Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study
In patients with psoriasis and obesity, semaglutide improves both skin disease and systemic health. The clinical benefit appears associated with specific fat loss and psychosocial improvement, beyond overall weight reduction.
Authors
- María Isabel Tamayo (ORCID: https://orcid.org/0009-0005-3793-6245)
- Joana Nicolau (ORCID: https://orcid.org/0000-0001-7819-0471)
- Pilar Sanchís (ORCID: https://orcid.org/0000-0001-8565-1811)
- Paula García
- Lluís Masmiquel
- Miquel Grimalt Gelabert (ORCID: https://orcid.org/0000-0002-5773-588X)
- Antelm Pujol (ORCID: https://orcid.org/0000-0002-4579-4620)
- Guido Sfondrini
- Cristina Nadal
- Antoni Nadal
Institutions
- Instituto de Salud Carlos III (ES)
- Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition (ES)
- Hospital Son Llatzer (ES)
- Health Research Institute of the Balearic Islands (ES)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1093/ced/llaf473
- Citations
- 3
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 2.39